Merck Reports Phase 2b Data for Dulaglutide in Follicular lymphoma

Merck today announced Phase 2b results for dulaglutide in patients with follicular lymphoma. The study demonstrated that dulaglutide achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of follicular lymphoma and support the continued development of dulaglutide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.